#United States #Salt Lake City #Lipocine #TLANDO #BRLIZIO

Lipocine Inc. Reports Financial Results for Q3 2026

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company dedicated to developing innovative oral therapeutics, recently disclosed its financial performance for the third quarter ending September 30, 2026. The report not only presents their fiscal results but also sheds light on the recent advancements in their product pipeline, particularly focusing on treatments targeting postpartum depression and major depressive disorders.

Recent Developments

LPCN 1154 (BRLIZIO™) for Postpartum Depression

In September, Lipocine launched the BLOOM study, a Phase 3 clinical trial designed to evaluate the effectiveness and safety of LPCN 1154 for postpartum depression (PPD). This placebo-controlled outpatient study aims to enroll around 120 participants and is aligned with the company's goal to submit a New Drug Application (NDA) under the 505(b)(2) pathway. Following constructive feedback from the FDA regarding the study design, Lipocine has incorporated necessary adjustments to enhance the trial's robustness.

The recent meeting with the FDA also confirmed that the submitted NDA package is nearly complete, pending the success of this trial. Furthermore, Lipocine is actively pursuing partnerships to facilitate the development and commercialization of BRLIZIO™.

Other Neuroactive Steroid Programs

LPCN 2201 for Major Depressive Disorder (MDD)

After assessing unique oral formulations of brexanolone, Lipocine intends to submit a Phase 2 study protocol to the FDA for LPCN 2201, aimed at treating major depressive disorder, contingent on resource allocation.

LPCN 2203 for Essential Tremor (ET)

The company completed pharmacokinetic studies for LPCN 2203 and plans to submit a proof-of-concept Phase 2 study protocol to the FDA for essential tremor, also depending on ongoing resource prioritization.

TLANDO® Updates

In a significant milestone, Health Canada approved TLANDO® (testosterone undecanoate) for testosterone replacement therapy in adult males suffering from conditions related to low endogenous testosterone levels. Verity Pharma, Lipocine's North America partner, is preparing for a Canadian launch in early 2027. Simultaneously, Pharmalink, Lipocine’s distributor, received marketing approval in the UAE for TESTYRA® (TLANDO) and aims for a 2027 launch there as well.

Lipocine is also exploring opportunities to partner TLANDO in additional global markets outside of the U.S., Canada, South Korea, the GCC countries, and Brazil.

Third Quarter Financial Results Ending September 30, 2026

As of the end of Q3 2026, Lipocine reported $21.5 million in unrestricted cash, cash equivalents, and marketable investment securities, a notable increase from $14.9 million at the close of 2025. The company also noted a rise in this figure to approximately $28.5 million by November 4, 2026, based on unaudited figures.

Lipocine recorded a net loss of $0.7 million, equating to a loss per diluted share of $0.08 for Q3 2026, a considerable improvement compared to the $3.2 million loss ($0.59 per diluted share) reported in the same period last year. Notably, the company recognized total revenues of $2.3 million in Q3 2026, derived from $2.1 million in licensing and collaboration revenues and $190,000 from TLANDO sales. This is a significant jump from just $115,000 reported in Q3 2025, which was entirely royalty income from TLANDO.

Research and development expenditures ranged at $2.1 million for this quarter, down from $2.7 million in the same quarter last year, primarily due to reduced costs associated with the LPCN 2401 study, which has been on hold since 2025. However, this was partly offset by increased costs relating to LPCN 1154 clinical studies.

General and administrative expenses rose to $1.1 million from $0.8 million, mainly driven by heightened personnel costs and legal fees associated with intellectual property protection and corporate strategy deployment. Interest and investment income remained stable at $0.2 million for both Q3 2026 and 2025.

Nine-Month Financial Highlights

Within the nine months concluding on September 30, 2026, Lipocine accumulated a net loss of $7.0 million, translating to a loss of $0.90 per diluted share. Comparatively, the preceding year reported a net loss of $7.3 million ($1.35 per diluted share). Notably, total revenue climbed to $2.6 million in this period, significantly up from $831,000 in 2025, fueled by increased licensing revenue and royalties from TLANDO sales.

Ongoing investments in research and development were reflected in increased nine-month expenditures totaling $6.9 million, marking an uptick from $5.9 million in the prior year. Furthermore, general and administrative expenses increased to $3.3 million from $2.8 million, following a trend of rising legal fees for intellectual property and functional personnel expenses.

For additional insights into Lipocine's detailed financial results for the three and nine months ended September 30, 2026, refer to the company’s latest Form 10-Q filed with the SEC.

Conclusion

Lipocine Inc. remains unwavering in its commitment to address unmet medical needs through innovative oral therapeutics. With a solid financial foundation and promising developmental programs on the horizon, the company is poised for significant advancements in the pharmaceutical landscape. For further information on Lipocine's ongoing projects and financial performance, please visit www.lipocine.com.